Anixa Biosciences Ownership

ANIX Stock  USD 3.30  0.01  0.30%   
Anixa Biosciences holds a total of 32.18 Million outstanding shares. Anixa Biosciences shows 5.05 percent of its outstanding shares held by insiders and 17.4 percent owned by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
 
Shares in Circulation  
First Issued
1985-12-31
Previous Quarter
31.9 M
Current Value
32.1 M
Avarage Shares Outstanding
M
Quarterly Volatility
8.9 M
 
Black Monday
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Some institutional investors establish a significant position in stocks such as Anixa Biosciences in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Anixa Biosciences, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.
Dividend Yield is likely to drop to 0.000022 in 2024. Dividend Payout Ratio is likely to drop to -0.0001 in 2024. Common Stock Shares Outstanding is likely to rise to about 37.4 M in 2024, whereas Net Loss is likely to drop (12.8 M) in 2024.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Anixa Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.
For more information on how to buy Anixa Stock please use our How to Invest in Anixa Biosciences guide.

Anixa Stock Ownership Analysis

About 17.0% of the company shares are held by institutions such as insurance companies. The book value of Anixa Biosciences was presently reported as 0.68. The company recorded a loss per share of 0.39. Anixa Biosciences had not issued any dividends in recent years. The entity had 1:25 split on the 26th of June 2015. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California. Anixa Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. For more info on Anixa Biosciences please contact Amit Kumar at 408 708 9808 or go to https://www.anixa.com.
Besides selling stocks to institutional investors, Anixa Biosciences also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Anixa Biosciences' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Anixa Biosciences' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.

Anixa Biosciences Quarterly Liabilities And Stockholders Equity

22.91 Million

Anixa Biosciences Insider Trades History

About 5.0% of Anixa Biosciences are currently held by insiders. Unlike Anixa Biosciences' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Anixa Biosciences' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Anixa Biosciences' insider trades
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Anixa Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Anixa Biosciences is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Anixa Biosciences backward and forwards among themselves. Anixa Biosciences' institutional investor refers to the entity that pools money to purchase Anixa Biosciences' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Shares
Bank Of New York Mellon Corp2024-06-30
73 K
Northern Trust Corp2024-09-30
71 K
Morgan Stanley - Brokerage Accounts2024-06-30
69 K
Corecap Advisors, Llc2024-06-30
46.9 K
Tyler-stone Wealth Management2024-09-30
42 K
Cambridge Invest Research Advisors, Inc.2024-09-30
41.1 K
International Assets Investment Management, Llc2024-09-30
37.8 K
Ci Private Wealth Llc2024-06-30
37.4 K
Gemmer Asset Management Llc2024-06-30
35 K
Vanguard Group Inc2024-09-30
1.4 M
Davidson D A & Co2024-06-30
736.4 K
Note, although Anixa Biosciences' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Anixa Biosciences Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Anixa Biosciences insiders, such as employees or executives, is commonly permitted as long as it does not rely on Anixa Biosciences' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Anixa Biosciences insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Catelani Michael over a month ago
Acquisition by Catelani Michael of 500000 shares of Anixa Biosciences subject to Rule 16b-3
 
Titterton Lewis H Jr over a month ago
Disposition of 16000 shares by Titterton Lewis H Jr of Anixa Biosciences at 2.575 subject to Rule 16b-3
 
Titterton Lewis H Jr over three months ago
Acquisition by Titterton Lewis H Jr of 5580 shares of Anixa Biosciences at 3.23 subject to Rule 16b-3
 
Titterton Lewis H Jr over three months ago
Acquisition by Titterton Lewis H Jr of 21646 shares of Anixa Biosciences at 3.06 subject to Rule 16b-3
 
Titterton Lewis H Jr over three months ago
Acquisition by Titterton Lewis H Jr of 796 shares of Anixa Biosciences at 2.81 subject to Rule 16b-3
 
Titterton Lewis H Jr over three months ago
Acquisition by Titterton Lewis H Jr of 405 shares of Anixa Biosciences at 2.7 subject to Rule 16b-3
 
Amit Kumar over six months ago
Acquisition by Amit Kumar of 28000 shares of Anixa Biosciences at 2.11 subject to Rule 16b-3
 
Amit Kumar over six months ago
Disposition of 1500000 shares by Amit Kumar of Anixa Biosciences subject to Rule 16b-3
 
Lewis Titterton over six months ago
Acquisition by Lewis Titterton of 15009 shares of Anixa Biosciences at 3.28 subject to Rule 16b-3
 
Michael Catelani over six months ago
Acquisition by Michael Catelani of 500000 shares of Anixa Biosciences at 2.74 subject to Rule 16b-3
 
Lewis Titterton over six months ago
Acquisition by Lewis Titterton of 45000 shares of Anixa Biosciences at 4.84 subject to Rule 16b-3
 
Amit Kumar over six months ago
Acquisition by Amit Kumar of 1000000 shares of Anixa Biosciences at 2.83 subject to Rule 16b-3

Anixa Biosciences Outstanding Bonds

Anixa Biosciences issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Anixa Biosciences uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Anixa bonds can be classified according to their maturity, which is the date when Anixa Biosciences has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Anixa Biosciences Corporate Filings

8K
8th of November 2024
Report filed with the SEC to announce major events that shareholders should know about
ViewVerify
F4
23rd of October 2024
The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities
ViewVerify
10Q
6th of September 2024
Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations
ViewVerify
F3
3rd of May 2024
The schedule filed by any person or group who acquires beneficial ownership of more than 5% of a voting class of a company's equity securities registered under Section 12 of the Act
ViewVerify

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Anixa Stock Analysis

When running Anixa Biosciences' price analysis, check to measure Anixa Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Anixa Biosciences is operating at the current time. Most of Anixa Biosciences' value examination focuses on studying past and present price action to predict the probability of Anixa Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Anixa Biosciences' price. Additionally, you may evaluate how the addition of Anixa Biosciences to your portfolios can decrease your overall portfolio volatility.